 Schrödinger Inc NASDAQ: SDGR and Zai Lab Limited NASDAQ: ZLAB have collaborated to discover, develop, and commercialize oncology candidate targeting DNA damage response. The research program will be conducted jointly by the Schrödinger and Zai Lab scientific teams. 